Public preview. Funding rounds, founders, and growth signals require a free account.

Delphia Therapeutics

Biotech company pioneering activation lethality, a precision medicine approach targeting cancer's vulnerability to oncogene overactivation.

Series ABiotechCambridge, MA

Last round

Series A

May 2024

Stage

Series A

Status

Active

Founders & team

Co-founder, CEO

Co-founder, CTO

Head of Engineering

Head of Sales

🔒

Free account unlocks founder names, LinkedIn profiles, and prior companies.

Web traffic

Search interest

Social followers

Glassdoor rating

News mentions

Gov contracts

🔒

Free account unlocks 5 full profiles per day. Pro removes the limit.

Get notified the moment Delphia Therapeutics files a new round, hires execs, or shows traction signals.

About this data

FlareSight surfaces funding data from SEC Form D filings within hours of submission. Browse our full startup funding database to find more recently funded companies.